Global Non-Invasive Prenatal Testing Market Analysis- Ken Research
According to the report analysis, ‘Global Non-invasive Prenatal Testing (NIPT) Market Forecast to 2025’ states that the global non-invasive prenatal the testing market will increase at a CAGR of 17.5% during the forecast period of 2019-2025. The effective benefits linked with the usage of these tests such as leading to an effective reduction in the number of expensive and risky invasive amniocentesis and Chorionic Villus Sampling (CVS) procedures are expected to enhance the volumetric abilities of the market at a global level which unswervingly translate into the growth in revenue for this market at a superior level.
The growth in this market is accredited to the augmented the customer acceptance of NIPT processes coupled with the extension in the allocation services of the operating individuals which allows them to materially seizure the potential NIPT opportunity.
Furthermore, the market has observed the balanced growth in the past few years and enhancement in technology with the institution of progressive products has augmented the implementation of non-invasive prenatal testing products in the market. The market is fostered by an expansion in the number of newborns with chromosomal syndromes owing to the augmenting the number of late pregnancies and increasing the requirement for non-invasive processes for early diagnosis.
The global market endures to increase, and NIPT is among the maximum extensively utilized the techniques for detecting genetic disorders in the fetal juncture, which will support the proper management of disease throughout the preliminary period of the gestation. The area is getting transfigured with the improvement in technology. Vendors are aiming at the new product introductions, product approvals, and targeting end-user’s standpoint. The market produces revenue from the foremost players operating in this sector, and few of them involve Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., F. Hoffmann-La Roche Ltd., and Beijing Genomics Institute.
Based on the region, in 2018, North America registered for the foremost share in the global non-invasive prenatal testing market and will remember an extraordinary position during the review period. According to WHO prediction, the pervasiveness of Down syndrome is between 1 in 1,000 and 1 in 1,100 live births across the globe. The occurrence of Down syndrome is 1 in 212 with the women age between 35 and 39 and the peril significantly augments with maternal age, i.e., above 45, the commonness rate is 1 in 33 newborns.
But the peril rate is very stumpy in fresher women in the age group of 24-25 years with occurrence rate decreased to 1 in 1429. The hazard of aneuploidy also augments with maternal age with an occurrence rate of 1 in 192 for women in the age category of 35 years and 1 in 66 in the age group up of 40. Auspicious reimbursement policies, accessibility of progressive technologies, the existence of protuberant vendors, and an augment in the pervasiveness of genetic disorders will raise the acceptance and requirement for tests in this region.
Asia Pacific is anticipated to increase at a high CAGR during the forecast period, due to the factors such as augmenting the consciousness of early disease diagnosis, accumulative healthcare expenditure, and occurrence of the huge population base. Therefore, in the near future, it is anticipated that the market of non-invasive prenatal testing (NIPT) across the globe more positively over the forecasted period.
To Know More, Click On The Link Below:-
Ankur Gupta, Head Marketing & Communications